Thomas Mandrup-Poulsen

List of Publications by Year
in descending order

175 papers	15,003 citations	17429 63 h-index	18633 119 g-index
181 all docs	181 docs citations	181 times ranked	16348 citing authors

#	Article	IF	Citations
1	Interleukin-1â€“Receptor Antagonist in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2007, 356, 1517-1526.	13.9	1,579
2	A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia, 2001, 44, 2115-2133.	2.9	782
3	A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831.	7.0	506
4	Cytokines Downregulate the Sarcoendoplasmic Reticulum Pump Ca2+ ATPase 2b and Deplete Endoplasmic Reticulum Ca2+, Leading to Induction of Endoplasmic Reticulum Stress in Pancreatic Â-Cells. Diabetes, 2005, 54, 452-461.	0.3	471
5	Interleukin-6 and Diabetes: The Good, the Bad, or the Indifferent?. Diabetes, 2005, 54, S114-S124.	0.3	442
6	An immune origin of type 2 diabetes?. Diabetologia, 2005, 48, 1038-1050.	2.9	384
7	Inflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetes. Journal of Molecular Medicine, 2003, 81, 455-470.	1.7	379
8	Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes. Diabetes Care, 2009, 32, 1663-1668.	4.3	347
9	Affinity-purified human Interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia, 1986, 29, 63-67.	2.9	314
10	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, The, 2013, 381, 1905-1915.	6.3	301
11	Role of IL-1Î² in type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 314-321.	1.2	284
12	Poor Pregnancy Outcome in Women With Type 2 Diabetes. Diabetes Care, 2005, 28, 323-328.	4.3	255
13	The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia, 2010, 53, 10-20.	2.9	252
14	Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of Î²-Cell Function in Therapeutic Trials in Type 1 Diabetes. Diabetes Care, 2008, 31, 1966-1971.	4.3	250
15	Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes. Diabetes Care, 2012, 35, 1654-1662.	4.3	237
16	Targeting innate immune mediators in type 1 and type 2 diabetes. Nature Reviews Immunology, 2019, 19, 734-746.	10.6	237
17	Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus. Molecular Medicine, 2011, 17, 378-390.	1.9	217
18	Proliferation of sorted human and rat beta cells. Diabetologia, 2007, 51, 91-100.	2.9	213

#	Article	IF	Citations
19	Blockade of interleukin 1 in type 1 diabetes mellitus. Nature Reviews Endocrinology, 2010, 6, 158-166.	4.3	204
20	Cytokines and Î²-Cell Biology: from Concept to Clinical Translation. Endocrine Reviews, 2008, 29, 334-350.	8.9	201
21	Proinflammatory Cytokines Activate the Intrinsic Apoptotic Pathway in Î²-Cells. Diabetes, 2009, 58, 1807-1815.	0.3	195
22	Cytokines Cause Functional and Structural Damage to Isolated Islets of Langerhans. Allergy: European Journal of Allergy and Clinical Immunology, 1985, 40, 424-429.	2.7	179
23	TiSH â€" a robust and sensitive global phosphoproteomics strategy employing a combination of TiO2, SIMAC, and HILIC. Journal of Proteomics, 2012, 75, 5749-5761.	1.2	174
24	RNA modifications by oxidation: A novel disease mechanism?. Free Radical Biology and Medicine, 2012, 52, 1353-1361.	1.3	174
25	Suppressor of Cytokine Signaling-3 Inhibits Interleukin-1 Signaling by Targeting the TRAF-6/TAK1 Complex. Molecular Endocrinology, 2006, 20, 1587-1596.	3.7	153
26	Glucose- and Interleukin-1Â-Induced Â-Cell Apoptosis Requires Ca2+ Influx and Extracellular Signal-Regulated Kinase (ERK) 1/2 Activation and Is Prevented by a Sulfonylurea Receptor 1/Inwardly Rectifying K+ Channel 6.2 (SUR/Kir6.2) Selective Potassium Channel Opener in Human Islets. Diabetes, 2004, 53, 1706-1713.	0.3	149
27	Interleukin-1Î²-induced Rat Pancreatic Islet Nitric Oxide Synthesis Requires Both the p38 and Extracellular Signal-regulated Kinase 1/2 Mitogen-activated Protein Kinases. Journal of Biological Chemistry, 1998, 273, 15294-15300.	1.6	145
28	Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia, 2005, 48, 251-260.	2.9	144
29	Apoptosis and the pathogenesis of IDDM: a question of life and death. Diabetes, 1998, 47, 1537-1543.	0.3	141
30	Divalent Metal Transporter 1 Regulates Iron-Mediated ROS and Pancreatic Î² Cell Fate in Response to Cytokines. Cell Metabolism, 2012, 16, 449-461.	7.2	133
31	Suppressor of cytokine signaling 3 (SOCS-3) protects Â-cells against interleukin-1Â- and interferon-Â-mediated toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 12191-12196.	3.3	131
32	Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia, 2005, 48, 2039-2050.	2.9	130
33	Apoptotic signal transduction pathways in diabetes. Biochemical Pharmacology, 2003, 66, 1433-1440.	2.0	126
34	Cytokine-Induced Proapoptotic Gene Expression in Insulin-Producing Cells Is Related to Rapid, Sustained, and Nonoscillatory Nuclear Factor-ÎºB Activation. Molecular Endocrinology, 2006, 20, 1867-1879.	3.7	124
35	Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia, 2007, 50, 779-789.	2.9	123
36	Dietary Supplementation with co-3-Polyunsaturated Fatty Acids Decreases Mononuclear Cell Proliferation and Interleukin-1beta Content but not Monokine Secretion in Healthy and Insulin-Dependent Diabetic Individuals. Scandinavian Journal of Immunology, 1991, 34, 399-410.	1.3	117

#	Article	IF	Citations
37	Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet, The, 2001, 358, 1405-1409.	6.3	117
38	Iron: the hard player in diabetes pathophysiology. Acta Physiologica, 2014, 210, 717-732.	1.8	105
39	Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans. Diabetologia, 1987, 30, 474-480.	2.9	102
40	The Oral Histone Deacetylase Inhibitor ITF2357 Reduces Cytokines and Protects Islet Î² Cells In Vivo and In Vitro. Molecular Medicine, 2011, 17, 369-377.	1.9	99
41	Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. European Journal of Endocrinology, 1986, 113, 551-558.	1.9	98
42	Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade. Diabetes, 2012, 61, 145-154.	0.3	98
43	Helsinki alert of biodiversity and health. Annals of Medicine, 2015, 47, 218-225.	1.5	95
44	The HLAâ€IDDM association: Implications for etiology and pathogenesis of IDDM. Diabetes/metabolism Reviews, 1987, 3, 779-802.	0.4	93
45	Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic Î²-cell destruction in insulin-dependent diabetes mellitus. Cytokine, 1993, 5, 185-191.	1.4	93
46	The bimodal effect of interleukin 1 on rat pancreatic beta-cells â€“ stimulation followed by inhibition â€“ depends upon dose, duration of exposure, and ambient glucose concentration. European Journal of Endocrinology, 1988, 119, 307-311.	1.9	90
47	Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes, Obesity and Metabolism, 2015, 17, 703-707.	2.2	90
48	Increased reduction in fasting C-peptide is associated with islet cell antibodies in Type 1 (insulin-dependent) diabetic patients. Diabetologia, 1985, 28, 875-880.	2.9	86
49	Cytokines and Pancreatic Î²-Cell Apoptosis. Advances in Clinical Chemistry, 2016, 75, 99-158.	1.8	85
50	The Fas pathway is involved in pancreatic beta cell secretory function. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2861-2866.	3.3	83
51	G Protein-Coupled Receptor 39 Deficiency Is Associated with Pancreatic Islet Dysfunction. Endocrinology, 2009, 150, 2577-2585.	1.4	82
52	Ageâ€dependent decline of Î²â€cell function in type 1 diabetes after diagnosis: a multiâ€centre longitudinal study. Diabetes, Obesity and Metabolism, 2014, 16, 262-267.	2.2	79
53	An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in Î²-Cell Protection. ACS Chemical Biology, 2016, 11, 363-374.	1.6	78
54	Mechanisms of Pancreatic Islet Cell Destruction Dose-Dependent Cytotoxic Effect of Soluble Blood Mononuclear Cell Mediators on Isolated Islets of Langerhans. Allergy: European Journal of Allergy and Clinical Immunology, 1986, 41, 250-259.	2.7	77

#	Article	IF	Citations
55	Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. Diabetologia, 2012, 55, 2421-2431.	2.9	77
56	High Glucose Suppresses Human Islet Insulin Biosynthesis by Inducing miR-133a Leading to Decreased Polypyrimidine Tract Binding Protein-Expression. PLoS ONE, 2010, 5, e10843.	1.1	76
57	Cytokines as Immune Effector Molecules in Autoimmune Endocrine Diseases with Special Reference to Insulin-Dependent Diabetes Mellitus. Autoimmunity, 1989, 4, 191-218.	1.2	75
58	Beta Cell Death and Protection. Annals of the New York Academy of Sciences, 2003, 1005, 32-42.	1.8	75
59	Iron Regulation of Pancreatic Beta-Cell Functions and Oxidative Stress. Annual Review of Nutrition, 2016, 36, 241-273.	4.3	73
60	Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays. Diabetologia, 1990, 33, 731-736.	2.9	70
61	Mitophagy protects Î² cells from inflammatory damage in diabetes. JCI Insight, 2020, 5, .	2.3	67
62	Cytokines and the endocrine system. I. The immunoendocrine network. European Journal of Endocrinology, 1995, 133, 660-671.	1.9	66
63	Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia, 2010, 53, 2569-2578.	2.9	66
64	IL-1Î² induced protein changes in diabetes prone BB rat islets of Langerhans identified by proteome analysis. Diabetologia, 2002, 45, 1550-1561.	2.9	65
65	Monocyte Function in IDDM Patients and Healthy Individuals. Scandinavian Journal of Immunology, 1990, 32, 297-311.	1.3	62
66	MicroRNAs as regulators of betaâ€cell function and dysfunction. Diabetes/Metabolism Research and Reviews, 2016, 32, 334-349.	1.7	62
67	Interleukin 1Î² induces diabetes and fever in normal rats by nitric oxide via induction of different nitric oxide synthases. Cytokine, 1994, 6, 512-520.	1.4	60
68	Elevated Transferrin Saturation and Risk of Diabetes: Three population-based studies. Diabetes Care, 2011, 34, 2256-2258.	4.3	60
69	Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and Î²-cell protection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1055-1059.	3.3	58
70	No direct effect of SGLT2 activity on glucagon secretion. Diabetologia, 2019, 62, 1011-1023.	2.9	58
71	Anti-cytokine therapies in T1D: Concepts and strategies. Clinical Immunology, 2013, 149, 279-285.	1.4	56
72	Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor ÎºB-mediated gene expression in insulin-producing INS-1E cells. Diabetologia, 2005, 48, 2582-2590.	2.9	55

#	Article	IF	Citations
73	Diabetes and Suppressors of Cytokine Signaling Proteins. Diabetes, 2007, 56, 541-548.	0.3	54
74	Interleukinâ€1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. European Journal of Immunology, 2016, 46, 1030-1046.	1.6	54
75	Iron Status and Gestational Diabetesâ€"A Meta-Analysis. Nutrients, 2018, 10, 621.	1.7	52
76	Endoplasmic Reticulum Chaperone Glucose-Regulated Protein 94 Is Essential for Proinsulin Handling. Diabetes, 2019, 68, 747-760.	0.3	52
77	Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1?-mediated toxicity through inhibition of multiple nuclear factor-?B-regulated proapoptotic pathways. Diabetologia, 2004, 47, 1998-2011.	2.9	51
78	Cardiovascular and All-Cause Mortality Risk Associated With Urinary Excretion of 8-oxoGuo, a Biomarker for RNA Oxidation, in Patients With Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care, 2017, 40, 1771-1778.	4.3	51
79	Interferon-Î³ Induces Interleukin-1 Converting Enzyme Expression in Pancreatic Islets by an Interferon Regulatory Factor-1-Dependent Mechanism1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 830-836.	1.8	49
80	Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury. Critical Care Medicine, 1995, 23, 26-33.	0.4	48
81	Interferon-Â Induces Interleukin-1 Converting Enzyme Expression in Pancreatic Islets by an Interferon Regulatory Factor-1-Dependent Mechanism. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 830-836.	1.8	45
82	Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes, 1998, 47, 1602-1608.	0.3	44
83	Glucolipotoxic conditions induce Î²-cell iron import, cytosolic ROS formation and apoptosis. Journal of Molecular Endocrinology, 2018, 61, 69-77.	1.1	44
84	Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. Human Molecular Genetics, 2003, 12, 1101-1110.	1.4	43
85	Altering Î²-cell number through stable alteration of miR-21 and miR-34a expression. Islets, 2014, 6, e27754.	0.9	42
86	Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. Journal of Biological Chemistry, 2018, 293, 14224-14236.	1.6	42
87	Nicotinamide treatment in the prevention of insulinâ€dependent diabetes mellitus. Diabetes/metabolism Reviews, 1993, 9, 295-309.	0.4	41
88	Over-expression of Follistatin-like 3 attenuates fat accumulation and improves insulin sensitivity in mice. Metabolism: Clinical and Experimental, 2015, 64, 283-295.	1.5	41
89	Skeletal Muscle to Pancreatic Î²-Cell Cross-talk: The Effect of Humoral Mediators Liberated by Muscle Contraction and Acute Exercise on Î²-Cell Apoptosis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1289-E1298.	1.8	39
90	The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 240-241.	2.9	37

#	Article	IF	Citations
91	Suppressor of cytokine signalling-3 inhibits tumor necrosis factor-alpha induced apoptosis and signalling in beta cells. Molecular and Cellular Endocrinology, 2009, 311, 32-38.	1.6	35
92	Serum adipokines as biomarkers of betaâ€cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin. Diabetes/Metabolism Research and Reviews, 2013, 29, 166-170.	1.7	35
93	Calcium Has a Permissive Role in Interleukin-1Î²-Induced c-Jun N-Terminal Kinase Activation in Insulin-Secreting Cells. Endocrinology, 2005, 146, 3026-3036.	1.4	34
94	IAPP boosts islet macrophage IL-1 in type 2 diabetes. Nature Immunology, 2010, 11, 881-883.	7.0	33
95	JNK1 Protects against Glucolipotoxicity-Mediated Beta-Cell Apoptosis. PLoS ONE, 2014, 9, e87067.	1.1	33
96	Indomethacin Treatment Prevents High Fat Diet-induced Obesity and Insulin Resistance but Not Glucose Intolerance in C57BL/6J Mice. Journal of Biological Chemistry, 2014, 289, 16032-16045.	1.6	33
97	Inhibition of beta cell growth and function by bone morphogenetic proteins. Diabetologia, 2014, 57, 2546-2554.	2.9	33
98	Interleukin-1Î²-induced nitric oxide production from isolated rat islets is modulated by D-glucose and 3-isobutyl-1-methyl xanthine. European Journal of Endocrinology, 1996, 134, 251-259.	1.9	32
99	Transcriptional and translational regulation of cytokine signaling in inflammatory Î²-cell dysfunction and apoptosis. Archives of Biochemistry and Biophysics, 2012, 528, 171-184.	1.4	32
100	Inhibition of Nuclear Factor-ÎºB or Bax Prevents Endoplasmic Reticulum Stress- But Not Nitric Oxide-Mediated Apoptosis in INS-1E Cells. Endocrinology, 2009, 150, 4094-4103.	1.4	31
101	Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients. Seminars in Immunopathology, 2019, 41, 413-425.	2.8	28
102	The intercellular adhesion molecule-1 K469E polymorphism in type 1 diabetes. Immunogenetics, 2000, 52, 107-111.	1.2	27
103	Is Puberty an Accelerator of Type 1 Diabetes in IL6-174CC Females?. Diabetes, 2005, 54, 1245-1248.	0.3	27
104	Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. Journal of Neuroinflammation, 2014, 11, 27.	3.1	26
105	The immunoproteasome is induced by cytokines and regulates apoptosis in human islets. Journal of Endocrinology, 2017, 233, 369-379.	1.2	26
106	Interleukin-1 potentiates glucose stimulated insulin release in the isolated perfused pancreas. European Journal of Endocrinology, 1988, 117, 302-306.	1.9	24
107	Increased Plasma Ferritin Concentration and Low-Grade Inflammationâ€"A Mendelian Randomization Study. Clinical Chemistry, 2018, 64, 374-385.	1.5	24
108	Type 2 Diabetes Mellitus. Dermatologic Clinics, 2013, 31, 495-506.	1.0	23

#	Article	IF	Citations
109	Lysine demethylase inhibition protects pancreatic Î² cells from apoptosis and improves Î²-cell function. Molecular and Cellular Endocrinology, 2018, 460, 47-56.	1.6	22
110	GLUTATHIONE DEPLETION INHIBITS IL-1Î²-STIMULATED NITRIC OXIDE PRODUCTION BY REDUCING INDUCIBLE NITRIC OXIDE SYNTHASE GENE EXPRESSION. Cytokine, 2000, 12, 1391-1394.	1.4	21
111	Cytokines and Type 1 Diabetes: A Numbers Game. Diabetes, 2011, 60, 697-699.	0.3	21
112	Apolipoprotein CIII Reduces Proinflammatory Cytokine-Induced Apoptosis in Rat Pancreatic Islets via the Akt Prosurvival Pathway. Endocrinology, 2011, 152, 3040-3048.	1.4	20
113	Interleukin-6 receptor blockade or TNFÎ± inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research and Therapy, 2020, 22, 206.	1.6	20
114	TRAF2 mediates JNK and STAT3 activation in response to IL-1Î² and IFNÎ³ and facilitates apoptotic death of insulin-producing Î²-cells. Molecular and Cellular Endocrinology, 2016, 420, 24-36.	1.6	19
115	Regulation of the Î²-cell inflammasome and contribution to stress-induced cellular dysfunction and apoptosis. Molecular and Cellular Endocrinology, 2018, 478, 106-114.	1.6	19
116	LINKAGE DISEQUILIBRIUM TESTING OF FOUR INTERLEUKIN-1 GENE-CLUSTER POLYMORPHISMS IN DANISH MULTIPLEX FAMILIES WITH INSULIN-DEPENDENT DIABETES MELLITUS. Cytokine, 2000, 12, 171-175.	1.4	18
117	Calcium- and Proteasome-dependent Degradation of the JNK Scaffold Protein Islet-brain 1. Journal of Biological Chemistry, 2003, 278, 48720-48726.	1.6	18
118	IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin. Diabetes Care, 2002, 25, 1192-1197.	4.3	17
119	MicroRNAs and histone deacetylase inhibition-mediated protection against inflammatory Î²-cell damage. PLoS ONE, 2018, 13, e0203713.	1.1	17
120	19F-heptuloses as tools for the non-invasive imaging of GLUT2-expressing cells. Archives of Biochemistry and Biophysics, 2012, 517, 138-143.	1.4	16
121	Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice. Diabetologia, 2018, 61, 389-398.	2.9	16
122	The No-Go and Nonsense-Mediated RNA Decay Pathways Are Regulated by Inflammatory Cytokines in Insulin-Producing Cells and Human Islets and Determine Î²-Cell Insulin Biosynthesis and Survival. Diabetes, 2018, 67, 2019-2037.	0.3	16
123	Interleukin-1 Antagonists and Other Cytokine Blockade Strategies for Type 1 Diabetes. Review of Diabetic Studies, 2012, 9, 338-347.	0.5	16
124	The Lysine Demethylase KDM5B Regulates Islet Function and Glucose Homeostasis. Journal of Diabetes Research, 2019, 2019, 1-15.	1.0	15
125	Interleukin-1 antagonists for diabetes. Expert Opinion on Investigational Drugs, 2013, 22, 965-979.	1.9	13
126	Total Mortality by Elevated Transferrin Saturation in Patients With Diabetes. Diabetes Care, 2013, 36, 2646-2654.	4.3	13

#	Article	IF	Citations
127	The intermediate proteasome is constitutively expressed in pancreatic beta cells and upregulated by stimulatory, low concentrations of interleukin 1ÂÎ². PLoS ONE, 2020, 15, e0222432.	1.1	13
128	Antitumorigenic Effect of Proteasome Inhibitors on Insulinoma Cells. Endocrinology, 2005, 146, 1718-1726.	1.4	12
129	RX871024 reduces NO production but does not protect against pancreatic Î²-cell death induced by proinflammatory cytokines. Biochemical and Biophysical Research Communications, 2006, 347, 1121-1128.	1.0	12
130	The lysine deacetylase inhibitor givinostat inhibits Î²-cell IL-1Î² induced IL-1Î² transcription and processing. Islets, 2012, 4, 417-422.	0.9	12
131	IL-1 receptor antagonism andÂmuscle gene expression inÂpatients withÂtype 2 diabetes. European Cytokine Network, 2009, 20, 81-87.	1.1	11
132	HDAC Inhibitor-Mediated Beta-Cell Protection Against Cytokine-Induced Toxicity Is STAT1 Tyr701 Phosphorylation Independent. Journal of Interferon and Cytokine Research, 2015, 35, 63-70.	0.5	11
133	Total and Cause-Specific Mortality by Elevated Transferrin Saturation and Hemochromatosis Genotype in Individuals With Diabetes: Two General Population Studies. Diabetes Care, 2014, 37, 444-452.	4.3	10
134	Age-dependent transition from islet insulin hypersecretion to hyposecretion in mice with the long QT-syndrome loss-of-function mutation Kcnq1-A340V. Scientific Reports, 2021, 11, 12253.	1.6	10
135	Absence of toxicity associated with adenoviral-mediated transfer of the Î²-galactosidase reporter gene to neonatal rat islets in vitro. Diabetes Research and Clinical Practice, 1999, 44, 157-163.	1.1	9
136	Direct demonstration of NCAMcis-dimerization and inhibitory effect of palmitoylation using the BRET²technique. FEBS Letters, 2011, 585, 58-64.	1.3	9
137	JNK1 Deficient Insulin-Producing Cells Are Protected against Interleukin-1Î²-Induced Apoptosis Associated with Abrogated Myc Expression. Journal of Diabetes Research, 2016, 2016, 1-15.	1.0	9
138	Metabolism and the inflammasome in health and ageing. Nature Reviews Endocrinology, 2018, 14, 72-74.	4.3	9
139	Neuromedin U Does Not Act as a Decretin in Rats. Cell Metabolism, 2019, 29, 719-726.e5.	7.2	9
140	Tissue Inhibitor Of Matrix Metalloproteinase-1 Is Required for High-Fat Diet-Induced Glucose Intolerance and Hepatic Steatosis in Mice. PLoS ONE, 2015, 10, e0132910.	1.1	9
141	Genetically determined differences in newborn rat islet sensitivity to interleukin-1 in vitro: no association with the diabetes prone phenotype in the BB-rat. European Journal of Endocrinology, 1989, 120, 92-98.	1.9	8
142	Similarities in expression levels of proteins in IL-1Î² stimulated BB-DP islets and islets syngrafted to BB-DP rats. Experimental and Clinical Endocrinology and Diabetes, 1997, 105, 9-9.	0.6	8
143	DEXAMETHASONE PREVENTS INTERLEUKIN-1Î²-MEDIATED INHIBITION OF RAT ISLET INSULIN SECRETION WITHOUT DECREASING NITRIC OXIDE PRODUCTION. Cytokine, 1997, 9, 563-569.	1.4	8
144	Endothelial Progenitor Cells in Long-Standing Asymptomatic Type 1 Diabetic Patients with or without Diabetic Nephropathy. Nephron Clinical Practice, 2011, 118, c309-c314.	2.3	8

#	Article	IF	Citations
145	Acute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice. Physiological Reports, 2018, 6, e13788.	0.7	8
146	Intra-Peritoneal Administration of Interleukin-1Î² Induces Impaired Insulin Release from the Perfused Rat Pancreas. Autoimmunity, 1990, 7, 1-12.	1.2	7
147	Process measures and outcome research as tools for future improvement of diabetes treatment quality. Diabetes Research and Clinical Practice, 2002, 56, 207-211.	1.1	7
148	The inducible Î²5i proteasome subunit contributes to proinsulin degradation in GRP94-deficient Î²-cells and is overexpressed in type 2 diabetes pancreatic islets. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E892-E900.	1.8	7
149	A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. PLoS ONE, 2016, 11, e0154727.	1.1	7
150	Interleukin-1Î² (IL-1) Does Not Reduce the Diabetes Incidence in Diabetes-Prone Bb Rats. Autoimmunity, 1994, 17, 105-118.	1.2	6
151	Skeletal muscle apolipoprotein B expression reduces muscular triglyceride accumulation. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 351-357.	0.6	6
152	Proinflammatory Cytokines Perturb Mouse and Human Pancreatic Islet Circadian Rhythmicity and Induce Uncoordinated Î²-Cell Clock Gene Expression via Nitric Oxide, Lysine Deacetylases, and Immunoproteasomal Activity. International Journal of Molecular Sciences, 2021, 22, 83.	1.8	6
153	Celebrities in the heart, strangers in the pancreatic beta cell: Voltageâ€gated potassium channels K_v7.1 and K_v11.1 bridge long QT syndrome with hyperinsulinaemia as well as type 2 diabetes. Acta Physiologica, 2022, 234, e13781.	1.8	6
154	Cytokine-mediated beta-cell destructionâ€"the molecular effector mechanism causing IDDM?. Journal of Autoimmunity, 1990, 3, 121-122.	3.0	5
155	Mutation Scan of a Type 1 Diabetes Candidate Gene. Annals of the New York Academy of Sciences, 2003, 1005, 332-339.	1.8	5
156	Need for Reclassification of Diabetes Secondary to Iron Overload in the ADA and WHO Classifications. Diabetes Care, 2014, 37, e137-e138.	4.3	5
157	Interleukin-1 Antagonism: A Sturdy Companion for Immune Tolerance Induction in Type 1 Diabetes?. Diabetes, 2014, 63, 1833-1835.	0.3	5
158	Urinary nucleic acid oxidation product levels show differential associations with pharmacological treatment in patients with type 2 diabetes. Free Radical Research, 2019, 53, 694-703.	1.5	5
159	The Connexin 43 Regulator Rotigaptide Reduces Cytokine-Induced Cell Death in Human Islets. International Journal of Molecular Sciences, 2020, 21, 4311.	1.8	5
160	Granzyme A in the Pathogenesis of Type 1 Diabetes: The Yes and the No. Diabetes, 2017, 66, 2937-2939.	0.3	4
161	Divalent Metal Transporter 1 Knock-Down Modulates IL-1Î² Mediated Pancreatic Beta-Cell Pro-Apoptotic Signaling Pathways through the Autophagic Machinery. International Journal of Molecular Sciences, 2021, 22, 8013.	1.8	4
162	The Autoimmune Hypothesis of Insulin-Dependent Diabetes: 1965 to the Present. E&M Endocrinology and Metabolism, 1990, , 1-28.	0.1	4

#	Article	IF	Citations
163	Attitudes towards diabetes and its care: Evaluation before, immediately post-course and ?1 year after a practical, international inter-disciplinary course for diabetes teams.. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, 39-44.	0.2	3
164	Perspective: Testing failures. Nature, 2012, 485, S17-S17.	13.7	3
165	Enhancer of Zeste Homolog 2 (EZH2) Mediates Glucolipotoxicity-Induced Apoptosis in Î²-Cells. International Journal of Molecular Sciences, 2020, 21, 8016.	1.8	3
166	Defective Proinsulin Handling Modulates the MHC I Bound Peptidome and Activates the Inflammasome in Î²-Cells. Biomedicines, 2022, 10, 814.	1.4	3
167	Serum Proteome Pool Changes in Type 2 Diabetic Patients Treated with Anakinra. Clinical Proteomics, 2010, 6, 153-161.	1.1	1
168	A Systematic Comparison of Purification and Normalization Protocols for Quantitative MicroRNA Expressional Profiling in Insulin-Producing Cells. International Journal of Molecular Sciences, 2016, 17, 896.	1.8	1
169	Combination of ferric ammonium citrate with cytokines involved in apoptosis and insulin secretion of human pancreatic beta cells related to diabetes in thalassemia. PeerJ, 2020, 8, e9298.	0.9	1
170	Title is missing!. , 2020, 15, e0222432.		0
171	Title is missing!. , 2020, 15, e0222432.		0
172	Title is missing!. , 2020, 15, e0222432.		0
173	Title is missing!. , 2020, 15, e0222432.		0
174	Title is missing!. , 2020, 15, e0222432.		0
175	Title is missing!. , 2020, 15, e0222432.		0